arrow
F

Finn Gustafsson

copenhagen university hospital
H指数:81
被引数:3.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Angiogenic biomarker concentrations and their relation to coronary atherosclerosis in women with a history of preeclampsia: Findings from the CPH-PRECIOUS study

子痫前期病史女性中血管生成生物标志物浓度及其与冠状动脉动脉粥样硬化的关系:CPH-PRECIOUS研究的结果

2026-09-140
OAAI
Interferon-gamma release assay screening before solid organ transplantation in a low-incidence country: a prospective single-center cohort study

在低流行国家实体器官移植前干扰素-γ释放试验筛查:一项前瞻性单中心队列研究

2026-06-060
OAAI
Survival Outcomes in Middle-aged and Older Patients with Advanced Heart Failure: A Propensity-Matched Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry

中老年晚期心力衰竭患者生存结局:基于MOMENTUM 3和UNOS登记研究的HeartMate 3左心室辅助装置与心脏移植的倾向性匹配分析

2026-05-100
OAAI
Clinical Application of Guideline-Directed Medical Therapy in TAVR Patients With Heart Failure and Reduced Ejection Fraction

指南指导的药物治疗在合并心力衰竭及射血分数降低的TAVR患者中的临床应用

2026-01-120
PRE
Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials (Vol 278,pg 106, 2024)
2025-12-010
OAAI
Impact of Atrial Fibrillation, Diabetes Mellitus and Obesity on Outcomes with Aspirin Avoidance and Hemocompatibility with a Left Ventricular Assist Device: An analysis from the ARIES-HM3 Trial

心房颤动、糖尿病和肥胖对停用阿司匹林及左心室辅助装置血液相容性影响的结果:一项来自ARIES-HM3试验的分析

2025-11-260
OAAI
Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial

左心室辅助装置且接受维生素K拮抗剂治疗的患者停用阿司匹林:随机ARIES-HM3试验中抗凝质量的影响

2025-11-011
OA
Multimodality imaging in advanced heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Part 1: Multimodality imaging for the evaluation of patients with advanced heart failure

心脏衰竭晚期中的多模态成像。欧洲心脏病学会心力衰竭协会的临床共识声明。第一部分:用于评估心脏衰竭晚期患者的多模态成像。

2025-10-140
PRE
Multimodality imaging in advanced heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Part 2: Mechanical circulatory support and heart transplantation

心力衰竭的多模态成像。欧洲心脏病学会心力衰竭协会的临床共识声明。第2部分:机械循环支持和心脏移植

2025-10-140
PRE
Worsening versus advanced heart failure: Management and challenges

恶化与进展性心力衰竭:管理与挑战

2025-10-040
OAAI
SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

SGLT2抑制剂在心力衰竭的预防和治疗中的应用:HFA和HFAI的科学声明

2025-09-190
OAAI
Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

主动脉瓣狭窄和慢性心力衰竭的管理:欧洲心力衰竭协会(HFA)和欧洲经皮心血管介入协会(EAPCI)的ESC临床共识声明

2025-09-150
PRE
Identifying and overcoming barriers to referral in advanced heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC

识别和克服心衰患者转诊中的障碍。欧洲心脏病学会(ESC)心力衰竭协会(HFA)的科学声明

2025-08-170
OAAI
A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial

一项关于pecavaptan(一种双重V1a/V2血管加压素受体拮抗剂)在急性心力衰竭患者中进行的多中心、随机、双盲、活性药物和安慰剂对照研究:AVANTI试验

2025-08-110
PRE